$XFOR News
Last published 1w ago
- 1w agoXFORX4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 - - Initiating 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor; Enrollment of First Participant Expected
- 1w agoXFORX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026GlobeNewswireBOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in several
- 1w agoXFORX4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor DayGlobeNewswire- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients - - On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 - - Planned 4STEPS
- 1mo agoXFORX4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersGlobeNewswireBOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual
- 1mo agoXFORX4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVenturesGlobeNewswire- Repayment of Existing Loan Facility Completed -- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End
- 2mo agoXFORX4 Pharmaceuticals Inc - Wells Fargo 21st Annual Healthcare Conference - X4 PHARMACEUTICALS INCEarnings Call TranscriptsAll right, everyone, I think we'll get started here with the next fireside discussion. My name is Derek Archilla. I'm one of the senior biotech analysts here at Wells. Very excited to have X4 Pharmaceuticals from the com
- 2mo agoXFORWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - X4 PHARMACEUTICALS INCEarnings Call TranscriptsAll right, everyone, I think we'll get started here with the next fireside discussion. My name is Derek Archilla. I'm one of the senior biotech analysts here at Wells. Very excited to have X4 Pharmaceuticals from the com
- 2mo agoXFORX4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare ConferenceGlobeNewswireBOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a
- 2mo agoXFORX4 Pharmaceuticals Announces Positive Outcome from FDA Type C MeetingGlobeNewswire- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)
- 2mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the
- 3mo agoXFORX4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized
- 3mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the
- 4mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the
- 4mo agoXFORCAMPX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsGlobeNewswireBOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the
- 5mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company
- 5mo agoXFORX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026
- 6mo agoXFORX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment
- 6mo agoXFORX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionGlobeNewswire- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29, 2026 (GLOBE
- 7mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the
- 8mo agoXFORX4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare ConferenceGlobeNewswireBOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate
- 8mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the
- 8mo agoXFORX4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeGlobeNewswire- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare
- 9mo agoXFORX4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026GlobeNewswireBOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in
- 9mo agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026,
- 1y agoXFORX4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation ConferenceGlobeNewswireBOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in
- 1y agoXFORX4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireCompany's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trialPreviously announced workforce reductions resulted in $13M annualized cost savingsSuccessful completion
- 1y agoXFORX4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 MillionGlobeNewswireBOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its
- 1y agoXFORX4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public OfferingGlobeNewswireBOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its
- 1y agoXFORX4 Pharmaceuticals Announces Proposed Underwritten Public OfferingGlobeNewswireBOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced
- 1y agoALTXFORAltimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of PemvidutideGlobeNewswireSeasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises
- 1y agoXFORX4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value CreationGlobeNewswireOrganizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his
- 1y agoABPCPIXXFORSitryx appoints Adam Mostafa as Chief Financial OfficerGlobeNewswireSitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8
- 1y agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025,
- 1y agoXFORX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementGlobeNewswireBOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of
- 1y agoXFORX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipGlobeNewswire$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as
- 1y agoXFORX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)GlobeNewswirePoster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were
- 1y agoXFORX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAGlobeNewswireBOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug
- 1y agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the
- 1y agoXFORX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressGlobeNewswireMeaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF
- 1y agoXFORX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswire4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful
- 1y agoXFORX4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025GlobeNewswireBOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial
- 1y agoXFORX4 Pharmaceuticals Announces Reverse Stock SplitGlobeNewswireBOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has
- 1y agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025,
- 1y agoXFORX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing
- 1y agoXFORX4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025GlobeNewswireBOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial
- 1y agoXFORX4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East CountriesGlobeNewswireBOSTON and DUBAI, United Arab Emirates, Feb. 19, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, and taiba rare, a
- 1y agoXFORX4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic NeutropeniaGlobeNewswireFull enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM syndrome community
- 1y agoXFORX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025,
- 1y agoXFORX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM SyndromeGlobeNewswireSubmission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE
- 1y agoXFORX4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New ZealandGlobeNewswireX4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties Upfront non-dilutive